Oligonucleotide-based Therapies Market 2028 By Type, Application and Geography | The Insight Partners

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oligonucleotide-based Therapies Market - By Type
1.3.2 Oligonucleotide-based Therapies Market - By Application
1.3.3 Oligonucleotide-based Therapies Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. OLIGONUCLEOTIDE-BASED THERAPIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - GLOBAL MARKET ANALYSIS
6.1. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET OVERVIEW
6.2. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTISENSE
7.3.1. Overview
7.3.2. Antisense Market Forecast and Analysis
7.4. RIBOZYMES
7.4.1. Overview
7.4.2. Ribozymes Market Forecast and Analysis
7.5. APTAMERS
7.5.1. Overview
7.5.2. Aptamers Market Forecast and Analysis
7.6. MIRNA
7.6.1. Overview
7.6.2. Mirna Market Forecast and Analysis
7.7. CPG/IMMUNOSTIMULATORY
7.7.1. Overview
7.7.2. CPG/Immunostimulatory Market Forecast and Analysis
7.8. RNAI.
7.8.1. Overview
7.8.2. RNAi. Market Forecast and Analysis
8. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. INFECTIOUS DISEASES
8.3.1. Overview
8.3.2. Infectious Diseases Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. NEURODEGENERATIVE DISORDERS
8.5.1. Overview
8.5.2. Neurodegenerative Disorders Market Forecast and Analysis
8.6. CARDIOVASCULAR DISEASES
8.6.1. Overview
8.6.2. Cardiovascular Diseases Market Forecast and Analysis
8.7. KIDNEY DISEASES
8.7.1. Overview
8.7.2. Kidney Diseases Market Forecast and Analysis
8.8. OTHERS.
8.8.1. Overview
8.8.2. Others. Market Forecast and Analysis

9. OLIGONUCLEOTIDE-BASED THERAPIES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oligonucleotide-based Therapies Market Overview
9.1.2 North America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.1.3 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.1.4 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.1.5 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Oligonucleotide-based Therapies Market
9.1.5.1.1 Canada Oligonucleotide-based Therapies Market by Type
9.1.5.1.2 Canada Oligonucleotide-based Therapies Market by Application
9.1.5.2 Mexico Oligonucleotide-based Therapies Market
9.1.5.2.1 Mexico Oligonucleotide-based Therapies Market by Type
9.1.5.2.2 Mexico Oligonucleotide-based Therapies Market by Application
9.1.5.3 US Oligonucleotide-based Therapies Market
9.1.5.3.1 US Oligonucleotide-based Therapies Market by Type
9.1.5.3.2 US Oligonucleotide-based Therapies Market by Application
9.2. EUROPE
9.2.1 Europe Oligonucleotide-based Therapies Market Overview
9.2.2 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis
9.2.3 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.2.4 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.2.5 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oligonucleotide-based Therapies Market
9.2.5.1.1 Germany Oligonucleotide-based Therapies Market by Type
9.2.5.1.2 Germany Oligonucleotide-based Therapies Market by Application
9.2.5.2 France Oligonucleotide-based Therapies Market
9.2.5.2.1 France Oligonucleotide-based Therapies Market by Type
9.2.5.2.2 France Oligonucleotide-based Therapies Market by Application
9.2.5.3 Italy Oligonucleotide-based Therapies Market
9.2.5.3.1 Italy Oligonucleotide-based Therapies Market by Type
9.2.5.3.2 Italy Oligonucleotide-based Therapies Market by Application
9.2.5.4 Spain Oligonucleotide-based Therapies Market
9.2.5.4.1 Spain Oligonucleotide-based Therapies Market by Type
9.2.5.4.2 Spain Oligonucleotide-based Therapies Market by Application
9.2.5.5 United Kingdom Oligonucleotide-based Therapies Market
9.2.5.5.1 United Kingdom Oligonucleotide-based Therapies Market by Type
9.2.5.5.2 United Kingdom Oligonucleotide-based Therapies Market by Application
9.2.5.6 Rest of Europe Oligonucleotide-based Therapies Market
9.2.5.6.1 Rest of Europe Oligonucleotide-based Therapies Market by Type
9.2.5.6.2 Rest of Europe Oligonucleotide-based Therapies Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oligonucleotide-based Therapies Market Overview
9.3.2 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis
9.3.3 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oligonucleotide-based Therapies Market
9.3.5.1.1 Australia Oligonucleotide-based Therapies Market by Type
9.3.5.1.2 Australia Oligonucleotide-based Therapies Market by Application
9.3.5.2 China Oligonucleotide-based Therapies Market
9.3.5.2.1 China Oligonucleotide-based Therapies Market by Type
9.3.5.2.2 China Oligonucleotide-based Therapies Market by Application
9.3.5.3 India Oligonucleotide-based Therapies Market
9.3.5.3.1 India Oligonucleotide-based Therapies Market by Type
9.3.5.3.2 India Oligonucleotide-based Therapies Market by Application
9.3.5.4 Japan Oligonucleotide-based Therapies Market
9.3.5.4.1 Japan Oligonucleotide-based Therapies Market by Type
9.3.5.4.2 Japan Oligonucleotide-based Therapies Market by Application
9.3.5.5 South Korea Oligonucleotide-based Therapies Market
9.3.5.5.1 South Korea Oligonucleotide-based Therapies Market by Type
9.3.5.5.2 South Korea Oligonucleotide-based Therapies Market by Application
9.3.5.6 Rest of Asia-Pacific Oligonucleotide-based Therapies Market
9.3.5.6.1 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Type
9.3.5.6.2 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oligonucleotide-based Therapies Market Overview
9.4.2 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis
9.4.3 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oligonucleotide-based Therapies Market
9.4.5.1.1 South Africa Oligonucleotide-based Therapies Market by Type
9.4.5.1.2 South Africa Oligonucleotide-based Therapies Market by Application
9.4.5.2 Saudi Arabia Oligonucleotide-based Therapies Market
9.4.5.2.1 Saudi Arabia Oligonucleotide-based Therapies Market by Type
9.4.5.2.2 Saudi Arabia Oligonucleotide-based Therapies Market by Application
9.4.5.3 U.A.E Oligonucleotide-based Therapies Market
9.4.5.3.1 U.A.E Oligonucleotide-based Therapies Market by Type
9.4.5.3.2 U.A.E Oligonucleotide-based Therapies Market by Application
9.4.5.4 Rest of Middle East and Africa Oligonucleotide-based Therapies Market
9.4.5.4.1 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Type
9.4.5.4.2 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oligonucleotide-based Therapies Market Overview
9.5.2 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.5.3 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.5.4 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.5.5 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oligonucleotide-based Therapies Market
9.5.5.1.1 Brazil Oligonucleotide-based Therapies Market by Type
9.5.5.1.2 Brazil Oligonucleotide-based Therapies Market by Application
9.5.5.2 Argentina Oligonucleotide-based Therapies Market
9.5.5.2.1 Argentina Oligonucleotide-based Therapies Market by Type
9.5.5.2.2 Argentina Oligonucleotide-based Therapies Market by Application
9.5.5.3 Rest of South and Central America Oligonucleotide-based Therapies Market
9.5.5.3.1 Rest of South and Central America Oligonucleotide-based Therapies Market by Type
9.5.5.3.2 Rest of South and Central America Oligonucleotide-based Therapies Market by Application

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. OLIGONUCLEOTIDE-BASED THERAPIES MARKET, KEY COMPANY PROFILES
11.1. PCI BIOTECH
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SOMAGENICS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. INTERNA TECHNOLOGIES
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. FRONTIERS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MIRAGEN THERAPEUTICS, INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IONIS PHARMACEUTICALS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ALIGOS THERAPEUTICS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GILEAD SCIENCES, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. BIOGEN INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. REGULUS THERAPEUTICS INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS